The Latest Breaking News from BMY

Bristol-Myers Squibb has underperformed the S&P 500 over the past year, and analysts are cautious about the stock’s prospects.

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

With the market looking a bit extended here, it could be a good idea to add some bearish trades to your options portfolio.

Bristol-Myers Squibb has been lagging behind other drug manufacturers over the past three months, and analysts remain cautious about the stock's prospects.

The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read…

Eli Lilly has outperformed the healthcare sector over the past three months, but analysts remain cautiously optimistic about the stock’s prospects.

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

Bristol-Myers Squibb stock has significantly trailed the broader market this year, and Wall Street remains wary on the stock’s prospects.

The pharma industry is poised for tremendous growth driven by surging healthcare needs, the introduction of groundbreaking medications, and relentless technological innovation. Hence, quality pharma stocks Collegium Pharmaceutical (COLL), Green Thumb Industries (GTBIF), and Bristol-Myers Squibb (BMY) emerge as prime investment options this month. Read more….